Synonyms: example 13 [US8293903] | PF-4634817 | PF04634817 | PF4634817
Compound class:
Synthetic organic
Comment: PF-04634817 is an oral dual CCR2/5 antagonist that was investigated for anti-inflammatory potential. The chemical structure of PF-04634817 is claimed (as example 13) in patent US8293903B2 [2].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Gale JD, Berger B, Gilbert S, Popa S, Sultan MB, Schachar RA, Girgenti D, Perros-Huguet C. (2018)
A CCR2/5 Inhibitor, PF-04634817, Is Inferior to Monthly Ranibizumab in the Treatment of Diabetic Macular Edema. Invest Ophthalmol Vis Sci, 59 (6): 2659-2669. [PMID:29847672] |
2. Hughes RO, Devraj RV, Rogier DJ, Trujillo JI, Turner SR, Huang W. (2012)
3-aminocyclopentanecarboxamides as chemokine receptor agonists. Patent number: US8293903B2. Priority date: 26/11/2008. Publication date: 23/10/2012. |
3. Romero-Aroca P, Baget-Bernaldiz M, Pareja-Rios A, Lopez-Galvez M, Navarro-Gil R, Verges R. (2016)
Diabetic Macular Edema Pathophysiology: Vasogenic versus Inflammatory. J Diabetes Res, 2016: 2156273. [PMID:27761468] |